8 rezultatima
Preeclampsia is a multisystem disorder that complicates 3-5% of pregnancies and remains a major cause of maternal, fetal, and neonatal morbidity and mortality.(1)
Preeclampsia is characterized by the development of new onset hypertension (HTN) and the establishment of proteinuria. Other signs and
Study Design: The study is a prospective, un-blinded, randomized interventional clinical trial comparing ModMeD to standard cardiac diet in 48 (24 per arm) inpatients with type II DM scheduled for CABG at MMC and who are scheduled to stay in the hospital for four (4) or more days prior to
At admission eligible patients are proposed to participate. Written consent is signed after complete oral and written explanation of the protocol is signed.
The efficacity of the cardiovascular active prevention will be studied by comparing the rate of Event free Survival between patients in the
Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks' postpartum. It is clinically defined by as blood pressure ≥140 mmHg systolic and ≥90 mmHg diastolic diagnosed for the first time after
Rapidly growing aging society augmented the risk of age-associated disorders, such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. Dietary interventions that reduce daily energy intake, also known as caloric restriction (CR), has been shown to be the most robust intervention to
Specific Aims
To test the global hypothesis that increases in insulin signaling through either PI-3-kinase or MAP kinase pathways correlate with improvements in NO production or NOS expression in skeletal muscle following pioglitazone therapy, we will determine whether 6 months of Pioglitazone
Background:
Patients with diabetes mellitus (DM) have an increased risk for atherothrombotic events.
Platelets play an important role in cardiovascular disease both in the pathogenesis of atherosclerosis and in the development of acute thrombotic events. Their importance in coronary heart disease is
BACKGROUND:
The results of many studies indicate that estrogen replacement therapy (ERT) reduces the risk of coronary heart disease (CHD) in postmenopausal women. However, less than 9 percent of these women choose to take ERT because of unwanted side effects and concerns about increased risk of